Gemcitabine Hydrochloride
3 NDCs across 3 manufacturers|3 Generic,0 Brand
Gemcitabine Hydrochloride is used to treat breast neoplasms, non-small-cell lung carcinoma, pancreatic ductal carcinoma and ovarian neoplasms, per the National Library of Medicine's MED-RT classification.
▸ More about this market▾ Less
The brand product was first FDA-approved on May 15, 1996, and the first generic was approved Nov 15, 2010.
Gemcitabine Hydrochloride is available as 3 NDCs from 3 manufacturers (3 generic, 0 brand), with NADAC prices from $20.00 to $20.00 per EA. Every pack size and labeler in this drug market is compared side-by-side below.
Total NDCs
3
3G / 0B
Manufacturers
3
competing in market
Price Spread
$20.00 – $20.00
per EA
7d Activity
avg +0.0% WoW · of 3 NDCs
Market Price Trend
Monthly average NADAC per unit, split by generic and brand.
Manufacturer Breakdown
3 manufacturers producing GEMCITABINE HYDROCHLORIDE
| Drug ↕ | Price | 7d Change ↕ |
|---|---|---|
GEMCITABINE HCL 1 GRAM VIAL | $19.9960 per EA | — |
GEMCITABINE HCL 1 GRAM VIAL | $19.9960 per EA | — |
GEMCITABINE HCL 1 GRAM VIAL | $19.9960 per EA | — |
Frequently Asked Questions
What is Gemcitabine Hydrochloride used to treat?
Gemcitabine Hydrochloride is used to treat breast neoplasms, non-small-cell lung carcinoma, pancreatic ductal carcinoma and ovarian neoplasms, per the National Library of Medicine's MED-RT classification.
When did Gemcitabine Hydrochloride become available as a generic?
FDA approved the first generic Gemcitabine Hydrochloride (ANDA) on Nov 15, 2010.
How many Gemcitabine Hydrochloride products are on the market?
The Gemcitabine Hydrochloride drug market contains 3 NDCs from 3 manufacturers — 3 generic and 0 brand products.
What is the price range for Gemcitabine Hydrochloride?
NADAC reference prices for Gemcitabine Hydrochloride range from $19.9960 to $19.9960 per EA.
Which manufacturers make Gemcitabine Hydrochloride?
3 manufacturers list Gemcitabine Hydrochloride in NADAC. Ranked by number of NDCs, the largest are NorthStar Rx LLC (1), Sagent Pharmaceuticals (1), Meitheal Pharmaceuticals Inc. (1).